Hyperactive bladder in multimorbid patients. What should be remembered?

Cover Page

Cite item

Full Text

Abstract

Multimorbidity (comorbidity) is a presence of two or more co-occurring chronic diseases in one patient that are pathogenically inter-related or simultaneous irrespective of disease activity. According to the World Health Organization analysis, between 2000 and 2050 years the percentage of people older than 60 years will double from 11% to 22%. The proportion of patients with comorbid chronic diseases will also increase. Apart from therapists, specialized doctors also face the problem of multimorbidity nowadays. The article discusses treatment of hyperactive bladder patients from the perspective of comorbidity and understanding of major diseases pathogenesis and pharmacologic agents pharmacokinetics.

About the authors

E. S Korshunova

National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation; Research Center of Neurology; Central State Medical Academy of the President of the Russian Federation

Email: e_korshunova@mail.ru
канд. мед. наук, ст. науч. сотр.; доц. каф. урологии 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 3; 125367, Russian Federation, Moscow, Volokolamskoe sh., d. 80; 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a

M. N Korshunov

Central State Medical Academy of the President of the Russian Federation; Russian-German Center for Reproduction and Clinical Embryology of Generation NEXT

канд. мед. наук, доц. каф. урологии; зав. андрологической лаб, Российско-немецкий центр репродукции и клинической эмбриологии 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a; 109544, Russian Federation, Moscow, ul. Shkol'naia, d. 40-42

References

  1. Van den Akker M, Buntinx F, Metsemakers J.F et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51 (5): 367-75.
  2. http://www.who.int/ageing/ageing-global-strategy-draft1-ru.pdf
  3. Верткин А.Л., Скотников А.С. Коморбидность. Лечащий врач. 2013; 8: 66-8.
  4. Von Stillfried D, Czihal T, Leibner M. Development of urology due to the demographic change. Praxisforum Urdogie. Leipzig. 29.09.2012.
  5. Ouslander J.G, Kane R.L, Abrass I.B. Urinary incontinence in elderly nursing home patients. JAMA 1982; 248: 1194-8.
  6. Diokno A.C, Estanol M.V.C, Ibrahim I.A et al. Prevalence of urinary incontinence in community dwelling men: a cross sectional nationwide epidemiological survey. Int Urol Nephrol 2007; 39: 129-36.
  7. Wu J.M, Vaughan C.P, Goode P.S et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstetr Gynecol 2014; 123: 141-8.
  8. Stewart W.F, Van Rooyen J.B, Cundiff G.W et al. Prevalence and burden of overactive bladder in the United States. W J Urol 2003; 20: 327-36.
  9. Irwin D.E, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306-14.
  10. Brown J.S, McGhan W.F, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl. 11): S574-9.
  11. Rubin E.B, Buehler A.E, Halpern S.D. States Worse Than Death Among Hospitalized Patients With Serious Illnesses. JAMA Intern Med 2016; 176 (10): 1557-9. doi: 10.1001/jamainternmed.2016.4362
  12. Лушникова Е.Л., Непомнящих Л.М., Неймарк А.И. и др. Роль структурно-функциональных изменений гладкомышечных клеток детрузора и предстательной железы в развитии гиперактивного мочевого пузыря. Фундаментальные исследования. 2012; 5 (1): 68-73.
  13. Коршунова Е.С. Диагностика и лечение симптомов нижних мочевых путей у больных болезнью Паркинсона в сочетании и без доброкачественной гиперплазии простаты. Автореф. дис. … канд. мед. наук. М., 2006.
  14. Lüthje P, Hirschberg A.L, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 2014; 77 (1): 32-6. doi: 10.1016/j.maturitas.2013.10.018
  15. Robinson D, Cardozo L, Milsom I et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014; 33 (7): 1086-91. doi: 10.1002/nau.22464
  16. Yamaguchi C, Sakakibara R, Uchiyama T et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn 2007; 26 (6): 807-13.
  17. Mansfield K.J, Liu L, Mitchelson F.J et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharm 2005; 144: 1089-99.
  18. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg’s Arch Pharmacol 2002; 366: 97-103.
  19. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337-43.
  20. Katz I.R, Sands L.P, Bilker W et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46 (1): 8-13.
  21. Womack K.B, Heilman K.M. Tolterodine and memory: dry but forgetful. Arch Neurol 2003; 60 (5): 771-3.
  22. Callegari E, Malhotra B, Bungay P.J et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72 (2): 235-46. doi: 10.1111/j.1365-2125.2011.03961.x
  23. Ferguson D.R, Kennedy I, Burton T.J. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism? J Physiol 1997; 505: 503-11.
  24. Hanna-Mitchell A.T, Beckel J.M, Barbadora S et al. Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 2007; 80: 2298-302.
  25. Kim Y, Yoshimura N, Masuda H et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2005; 97: 400-3.
  26. Ortiz de Montellano, Paul R. Cytochrome P450: structure, mechanism, and biochemistry. 3rd ed. New York: Kluwer Academic/Plenum Publishers, 2005.
  27. Guay D.R.P. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-85.
  28. Ohtake A, Saitoh C, Yuyama H. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007; 30: 54-8.
  29. Chapple C.R, Khullar V, Gabriel Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
  30. Crewe H.K, Lennard M.S, Tucker G.T. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992/09/01 ed. Br J Clin Pharmacol 1992; 34: 262-5.
  31. Yaïch M, Popon M, Médard Y. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics 1998; 8 (5): 449-51.
  32. Zanger U.M, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-41.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies